Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Vasopressin Versus Terlipressin as a Second Vasopressor in Critically Ill Cirrhotics With Septic Shock- the VITEL-C Trial.

NCT05315557 is registered in ClinicalTrials.gov with Institute of Liver and Biliary Sciences, India as lead sponsor.

NCT NCT05315557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05315557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Vasopressin Versus Terlipressin as a Second Vasopressor in Critically Ill Cirrhotics With Septic Shock- the VITEL-C Trial.
Lead sponsor
Institute of Liver and Biliary Sciences, India
Phase
Not applicable
Overall status
Unknown status
Start date
April 5, 2022
Completion date
March 31, 2023
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, liver, septic shock